Interview: Frank Douglas – CEO, TheVax Genetics, Taiwan

02.06.2017
Frank Douglas, CEO of the TheVax, discusses what he finds so inspiring about innovation in resource-constrained environments, and this Taiwanese biotech’s revolutionary SIT specific immunotherapy platform. The company was founded in 2012 with the mission to focus on the use of immunotherapy to address virus-induced tumors and infections in patients. Could you explain how the company was founded and how you became CEO of the TheVax Genetics Vaccine USA?
"The Specific Immunological Therapeutic (SIT) approach represents a technology platform with potential for application in several diseases."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Taiwan, TheVax, Biotech, Genetics, Immunotherapy, Innovation, R&D

Related Interviews

Louis Cheng – CEO, Leadgene Biomedical, Taiwan

Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…

Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…

Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…

Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…

Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are.    At MVC we have…

Related Articles

China / BioNTech-Fosun JV; Patent Law Revamp; Hong Kong as a Biotech Listing Hub

The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.…

Precision Medicine in Asia / More Regional Cooperation Needed

With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region…

First Impressions / Taiwanese Pharma

Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…

Latest Report

Denmark Pharma Report 2021

Related Content

Taiwan
TheVax
Biotech
Genetics
Immunotherapy
Innovation
R&D